PIN23 TREATING PATIENTS WITH DAAS ALLOWED TO SAVE 1 BILLION EUROS IN FRANCE - A BUDGET IMPACT MODEL FROM 2014 TO 2018.

Authors :: Leleu, H.
Rodriguez, I.
Blachier, M.
Bonnard, P.
Pol, S.
Roudot-Thoraval, F.
Source :: Value in Health. 2019 Supplement 3, Vol. 22, pS643-S643. 1p.
Publication Year :: 2019
Abstract: New Direct Acting Antivirals (DAA) constituted a breakthrough innovation in chronic hepatitis C (CHC) treatments. A budget impact (BI) model was constructed to estimate the BI of CHC between 2014 and 2018 and to extrapolate long-term (up to 40y) direct and indirect costs for treated CHC patients. [Extracted from the article]

Full Text Access

Tools